A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT07225946
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Prostatic Neoplasms, Castration-Resistant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pasritamig — DRUGPasritamig will be administered.
- Docetaxel — DRUGDocetaxel will be administered.
- Prednisone — DRUGPrednisone will be administered.
Study Details
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Key Dates
- Start date
- Dec 19, 2025
- Status verified
- Jun 2026
- Primary completion
- Nov 19, 2027
- Completion
- Jul 20, 2029
Study Design
- Enrollment
- 800 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Pasritamig+DocetaxelParticipants will receive pasritamig along with docetaxel until the end of trial (EOT) visit or until confirmed radiographic progression by blinded independent central review (BICR), or any other protocol defined criteria are met.
- Active Comparator: DocetaxelParticipants will receive docetaxel along with prednisone as background medication.
Primary Outcome Measure
Radiographic Progression-Free Survival (rPFS) Assessed by BICR [ Time Frame: Up to approximately 1 years 10 months ]
Central Contacts
- Study Contact844-434-4210
Locations (49)
Find similar trials in Chandler, AZ
Related Studies
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)PHASE1/PHASE2 · Recruiting · Clarity Pharmaceuticals Ltd · Stanford, California
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerPHASE1 · Recruiting · Weill Medical College of Cornell University · New York, New York
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerPHASE1/PHASE2 · Recruiting · Celcuity Inc · Detroit, Michigan